MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study

By Yahoo! Finance | Oct 16, 2024 at 05:04 PM EST

MeiraGTx's AAV-GAD gene therapy for Parkinson's disease met primary endpoint in a Phase I/II trial. High-dose group showed significant improvement in MDS-UPDRS score. The therapy aims to deliver GAD enzyme to reduce motor symptoms with a one-time infusion.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.